Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 3:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 569 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: K8 Clear all
Completed Phase 2 Interventional Results available

Safety and Effectiveness of Raltegravir Plus Darunavir/Ritonavir in Treatment-Naive HIV-Infected Adults

NCT00830804
View directory record Official record
Conditions
HIV-1 Infections
Interventions
Raltegravir, Darunavir/Ritonavir
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
22
States / cities
Birmingham, Alabama • Palo Alto, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2018 · Synced Oct 30, 2026, 3:55 PM EDT
Completed Not applicable Interventional

Controlling Blood Pressure in Treatment Resistant Hypertension: A Pilot Study

NCT02167464
View directory record Official record
Conditions
Hypertension
Interventions
Renin treatment-guided Therapeutics, Referral Hypertension specialist, Aldosterone Antagonist
Drug · Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
8
States / cities
Anderson, South Carolina • Beaufort, South Carolina • Florence, South Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2018 · Synced Oct 30, 2026, 3:55 PM EDT
Completed Phase 3 Interventional Results available

Study Comparing Lopinavir/Ritonavir (LPV/r) + Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) With a Nucleoside Sparing Regimen Consisting of Lopinavir/Ritonavir + Raltegravir (RAL)

NCT00711009
View directory record Official record
Conditions
Human Immunodeficiency Virus Infection
Interventions
lopinavir/ritonavir (LPV/r), emtricitabine/tenofovir disoproxil fumarate (FTC/TDF), raltegravir (RAL)
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
14
States / cities
Phoenix, Arizona • Beverly Hills, California • Atlantis, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2012 · Synced Oct 30, 2026, 3:55 PM EDT
Withdrawn Phase 3 Interventional Accepts healthy volunteers

Study of Thyroid Hormones in Prematures

NCT02103998
View directory record Official record
Conditions
Transient Hypothyroxinemia of Prematurity (THOP)
Interventions
thryoid hormone T4 + oral potassium iodide (KI) for 42 days, D5W - 5% dextrose water
Drug
Lead sponsor
New York Medical College
Other
Eligibility
1 Hour to 24 Hours
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Valhalla, New York
Source: ClinicalTrials.gov public record
Updated Apr 24, 2019 · Synced Oct 30, 2026, 3:55 PM EDT
Recruiting Phase 2 Interventional

Cardiac Effects of Mineralocorticoid Receptor Antagonism After Hypertensive Disorders of Pregnancy

NCT07238400
View directory record Official record
Conditions
Hypertension
Interventions
Eplerenone 100 mg daily, Chlorthalidone 25 mg daily, Potassium Placebo, Potassium Chloride
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 30, 2026, 3:55 PM EDT
Completed Phase 3 Interventional Results available

Moxifloxacin in Pediatric Subjects With Complicated Intra-abdominal Infection

NCT01069900
View directory record Official record
Conditions
Intraabdominal Infections
Interventions
Moxifloxacin (Avelox, BAY12-8039), Ertapenem, Amoxicillin/Clavulanate, Moxifloxacin placebo, Ertapenem placebo, Amoxicillin/Clavulanate placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
3 Months to 17 Years
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
2
States / cities
San Diego, California • Springfield, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 20, 2018 · Synced Oct 30, 2026, 3:55 PM EDT
Terminated Not applicable Interventional

Task or Virtual Reality Intervention for Improving UE Function

NCT03811275
View directory record Official record
Conditions
Upper Extremity Paresis, Hemiplegia and/or Hemiparesis Following Stroke, Hemiplegic Cerebral Palsy
Interventions
Virtual Reality (A) then Task (B), Task (B) then Virtual Reality (A)
Behavioral
Lead sponsor
Idaho State University
Other
Eligibility
18 Years to 89 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Pocatello, Idaho
Source: ClinicalTrials.gov public record
Updated Apr 30, 2024 · Synced Oct 30, 2026, 3:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effectiveness of Two Water-Based Potassium Oxalate Desensitizers

NCT02192307
View directory record Official record
Conditions
Dentin Sensitivity
Interventions
Potassium oxalate
Device
Lead sponsor
Procter and Gamble
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 5, 2019 · Synced Oct 30, 2026, 3:55 PM EDT
Withdrawn Phase 4 Interventional

CLCNKA (Ka Renal Chloride Channel[ClC-Ka]) Polymorphism Effects on Hypertrophy Regression

NCT01275352
View directory record Official record
Conditions
Hypertension
Interventions
Eplerenone, placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
40 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
St Louis, Missouri • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 3, 2015 · Synced Oct 30, 2026, 3:55 PM EDT
No Longer Available No phase listed Expanded access

131I-Metaiodobenzylguanidine (131I-MIBG) Therapy for Relapsed/Refractory Neuroblastoma

NCT03649438
View directory record Official record
Conditions
Relapsed Neuroblastoma, Metastatic Pheochromocytoma
Interventions
131 I-Metaiodobenzylguanidine, Potassium Iodide, G-csf
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced Oct 30, 2026, 3:55 PM EDT
Terminated Phase 3 Interventional Results available

Study of the Effect of SZC on Serum Potassium and Serum Bicarbonate in Patients With Hyperkalemia and Metabolic Acidosis Associated With Chronic Kidney Disease

NCT04727528
View directory record Official record
Conditions
Hyperkalaemia, Metabolic Acidosis, Chronic Kidney Disease
Interventions
Sodium zirconium cyclosilicate, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
29
States / cities
Florence, Alabama • Chula Vista, California • Downey, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2023 · Synced Oct 30, 2026, 3:55 PM EDT
Recruiting Phase 4 Interventional

Low Sodium Oxybate in Patients With Idiopathic Hypersomnia

NCT05837091
View directory record Official record
Conditions
Idiopathic Hypersomnia
Interventions
Low Sodium Oxybate, 24-hour polysomnography, Nextsense EEG earbuds, Axivity device
Drug · Diagnostic Test · Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
4
States / cities
Phoenix, Arizona • Redwood City, California • Jacksonville, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 30, 2026, 3:55 PM EDT
Not listed Not applicable Interventional

Dietary Sodium-Restriction (DIS) and Renal Meals (RM) for Hemodialysis (HD)(DISaRM-HD)

NCT04991441
View directory record Official record
Conditions
Kidney Failure, Chronic, Dietary Modification
Interventions
Controlled Dietary Sodium Restriction, Control Diet & Controlled Dietary Sodium Restriction
Dietary Supplement
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Urbana, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 5, 2021 · Synced Oct 30, 2026, 3:55 PM EDT
Completed Not applicable Interventional

Effects of a Whole-food, Plant-based Nutrition Program on BP and Potassium in Subjects With CKD

NCT06343129
View directory record Official record
Conditions
Chronic Kidney Diseases
Interventions
Dietary education program
Behavioral
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Oct 30, 2026, 3:55 PM EDT
Completed Phase 1 Interventional Results available

Safety, Blood Levels and Effects of AUT00201 in Patients With MEAK

NCT05873062
View directory record Official record
Conditions
Myoclonus Epilepsies, Progressive
Interventions
AUT00201, Placebo
Drug
Lead sponsor
Autifony Therapeutics Limited
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Oct 30, 2026, 3:55 PM EDT
Recruiting Phase 4 Interventional

A Prompt REstart Study of Renin-Angiotensin System Inhibitors After Acute Kidney Injury

NCT07734636
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Early RASi restart strategy, Usual Care
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 30, 2026, 3:55 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Investigate the Stain and Plaque Removal Capability of Two Experimental Potassium Nitrate Dentifrices

NCT03267511
View directory record Official record
Conditions
Oral Hygiene
Interventions
5% KNO3 / 0.2542% NaF dentifrice with 0.5% spherical silica, 5% KNO3 / 0.2542% NaF dentifrice with 1% spherical silica and 5% STP, 5% KNO3 / 0.2542% NaF dentifrice with 6% abrasive silica, 5% KNO3 / 0.2543% NaF dentifrice with 16% abrasive silica and 5% STP
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
123 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Fort Wayne, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Oct 30, 2026, 3:55 PM EDT
Terminated Phase 4 Interventional

Raltegravir (Isentress/MK-0518) and HIV-1 Infected CD4 Cells During Acute/Early HIV-1

NCT00781287
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
3-drug anti-HIV therapy, Raltegravir
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 12, 2013 · Synced Oct 30, 2026, 3:55 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Prospective Phenotyping of Autonomous Aldosterone Secretion

NCT03484130
View directory record Official record
Conditions
Aldosterone Disorder, Adrenal Gland Disease, Blood Pressure
Interventions
Sodium loaded diet, Restricted sodium diet
Dietary Supplement
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
35 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 30, 2026, 3:55 PM EDT
Recruiting Phase 1 Interventional

Preoperative Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal Tumor

NCT07171203
View directory record Official record
Conditions
Gastrointestinal Stromal Tumors
Interventions
Imatinib, Fampridine
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 30, 2026, 3:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Irradiated Blood Versus Non Irradiated Blood Transfusions in Craniosynostosis Repair

NCT02483702
View directory record Official record
Conditions
Graft Versus Host Disease, Hyperkalemia, Craniectomy, Synostectomy, FOA, Congenital Malformations
Interventions
Irradiated Blood Transfusions, Non-Irradiated Blood Transfusions
Other
Lead sponsor
Valley Anesthesiology Consultants
Other
Eligibility
2 Months to 6 Months
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 19, 2018 · Synced Oct 30, 2026, 3:55 PM EDT
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

Retention of Potassium From Potatoes and Potassium Gluconate, and the Effect on Blood Pressure.

NCT02697708
View directory record Official record
Conditions
Hypertensive Disease
Interventions
Potassium control diet, Potassium gluconate diet, Potato Diet, French Fries Diet
Dietary Supplement
Lead sponsor
Purdue University
Other
Eligibility
21 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated May 9, 2018 · Synced Oct 30, 2026, 3:55 PM EDT
Terminated Phase 2 Interventional Results available

Phase IIB Pilot of Atazanavir + Raltegravir

NCT00768989
View directory record Official record
Conditions
HIV
Interventions
Atazanavir, Raltegravir, Ritonavir, Tenofovir/Emtricitabine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
9
States / cities
Phoenix, Arizona • New Haven, Connecticut • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2012 · Synced Oct 30, 2026, 3:55 PM EDT
Terminated Phase 4 Interventional

Patiromer Utility as an Adjunct Treatment in Patients Needing Urgent Hyperkalemia Management

NCT04443608
View directory record Official record
Conditions
Hyperkalemia
Interventions
Patiromer Powder for Oral Suspension [Veltassa], Placebo
Drug
Lead sponsor
Comprehensive Research Associates
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
19
States / cities
Stanford, California • New Haven, Connecticut • Newark, Delaware + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2023 · Synced Oct 30, 2026, 3:55 PM EDT